Taken together, the histopathological and immune profiling studies indicate that i.v. transplantation of KL;ASC cells into C57BL/6 hosts (ASCi.v./C57BL/6) reliably recapitulates the source GEMM tumor phenotype, rendering it suitable to evaluate anti-cancer treatments for this aggressive subtype of NSCLC. This evidence concerns the gene KL and non-small cell lung carcinoma.